ADMA Biologics Inc vs Eaton Corporation plc — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while Eaton Corporation plc trades at $462.58 (market cap $172.82B). The key difference: Eaton Corporation plc is far larger — about 77.8× ADMA Biologics Inc's market cap, and Eaton Corporation plc pays a 0.99% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ETN | |
|---|---|---|
Market Cap | $2.22B | $172.82B |
Sector | Health | Technology |
52-Week High | $20.38 | $459.29 |
52-Week Low | $7.60 | $315.82 |
Enterprise Value | $2.29B | $193.45B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Eaton Corporation (ETN) trades at $468.37, up 5.26% in 24 hours, reflecting strong momentum after recent earnings beats. The stock exhibits a bullish technical trend with support at $456 and resistance at $470. Q2 2026 earnings beat expectations with EPS of $3.15 versus $3.07 estimated, and the company raised its full-year outlook, driven by robust demand in electrical and data center segments.
Outlook remains positive given raised guidance and AI-driven power infrastructure demand, but risks include premium valuation (P/E 45.31) and execution challenges. Analyst consensus is bullish with a $499.75 price target, though investors should monitor competitive pressures and macroeconomic conditions affecting industrial spending.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →